Cited by 967Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Open access

Peggs, Karl S., Quezada, Sergio A., Chambers, Cynthia A., Korman, Alan J., Allison, James P.·2009·Journal of Experimental Medicine

DOI 10.1084/jem.20082492PMC PMC2722174

Open this paper in CoChat — free account Open PDF

Abstract

Cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) is a critical negative regulator of immune responses. Uniquely among known inhibitory receptors, its genetic ablation results in a fulminating and fatal lymphoproliferative disorder. This central regulatory role led to the development of antibodies designed to block CTLA-4 activity in vivo, aiming to enhance immune responses against cancer. Despite their preclinical efficacy and promising clinical activity against late stage metastatic melanoma, the critical cellular targets for their activity remains unclear. In particular, debate has focused on whether the effector T cell (Teff) or regulatory T cell (T reg cell) compartment is the primary target of antibody-mediated blockade. We developed a mouse expressing human instead of mouse CTLA-4, allowing us to evaluate the independent contributions of CTLA-4 blockade of each T cell compartment during cancer immunotherapy in an in vivo model of mouse melanoma. The data show that although blockade on effector cells significantly improves tumor protection, unicompartmental blockade on regulatory cells completely fails to enhance antitumor responses. However, concomitant blockade of both compartments leads to a synergistic effect and maximal antitumor activity. We conclude that the combination of direct enhancement of Teff cell function and concomitant inhibition of T reg cell activity through blockade of CTLA-4 on both cell types is essential for mediating the full therapeutic effects of anti–CTLA-4 antibodies during cancer immunotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1084/jem.20082492

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citation
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,785
Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Self-citation
Modulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,375
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., & Nakayama, E. (1999) · PubMed · Cited by 1,062
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Self-citation

Flagged first, then by citations

Show all 34 references

1 of the 34 references couldn’t be matched to a known paper.

Sorted by citations

Items 901–967 of 967

Immune-Checkpoint Inhibitors: A New Line of Attack in Triple-Negative Breast Cancer
Jarroudi, O. A., Bairi, K. E., Curigliano, G., & Afqir, S. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_2
Definitive proton chemoradiotherapy in cervical esophageal tumors - a preliminary analysis results
Vítek, P., Kubeš, J., Jiránková, K., & Vondráček, V. (2024) · Onkologie · doi:10.36290/xon.2024.011
Deciphering the Role of Immune-Checkpoint Inhibitors in Lung Cancer Treatment
Sharma, P., Singh, N., & Sharma, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-3746-2_19
Immunobiology of Cancer
Verma, N., Thapa, K., Kanojia, N., & Chandel, P. (2024) · Springer eBooks · doi:10.1007/978-981-97-3001-8_2 · Cited by 1
Participation of Mesenchymal Stem Cells in the Tumor Process
Arenas-Luna, V. M., Cisneros, B., & Hernández-Gutiérrez, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-7119-0_37
LAG-3 in Cancer Immunotherapy: A Comprehensive Review
Tathe, P. R., Charhate, K. B., Laddha, P. R., & Sitaphale, G. R. (2024) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-19504
Progress of Immunotherapy Combined with Anti-Angiogenesis Therapy in Lung Cancer
Zuo, C., Xie, J., Wang, M., Cai, J., & Ye, Q. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.129018
The survival and safety of metastatic hepatocellular carcinoma treated with lenalidomide as second-line therapy: a case report and review of the literature
Li, T., Zhao, Y. X., Li, K., Li, G., & Li, G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1461936
Characteristics of the Immune Microenvironment and Progress in Immunotherapy for Triple-Negative Breast Cancer
贾, 书. (2025) · World Journal of Cancer Research · doi:10.12677/wjcr.2025.151004
Tumor Immunity and Monoclonal Antibody Therapies
Gao, J., Xu, Y., Li, Y., Yang, H., & Liu, W. (2025) · Springer eBooks · doi:10.1007/978-981-96-1027-3_9
Harnessing the immune system: Insights into cancer vaccines
Acharya, S. S., Bhal, S., Das, B., & Kundu, C. N. (2025) · Advances in immunology · doi:10.1016/bs.ai.2024.10.006
Enhanced potency of immune checkpoint inhibitors against poorly immunological solid tumors by immune stimulatory oncolytic adenoviruses-mediated remodeling of the tumor microenvironment
Ahn, H. M., Jung, B., Hong, J., Hong, D., Yoon, A. R., & Yun, C. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01223-4
Ectopic ULBP2 Is Associated with Decreased NKG2D Expression in CD8+ T Cells Under T Cell-Modulatory Conditions in a Murine Tumor Model
Teruya, Y., Yamaguchi, K., Yamane, K., Miyake, N., Nakayama, Y., Nonaka, T., Chikumi, H., & Yamasaki, A. (2025) · Cells · doi:10.3390/cells14120893 · Cited by 1
Incidence of pneumonitis with CTLA-4 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis
Li, W., Xiong, H., Peng, H., Yang, T., Fan, L., & Zhang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1614442
Immunotherapy in the Treatment of Melanoma
Katsouda, A., Rallis, T., Gogakos, A. S., Theocharidis, V., Kanteres, T., Tzinevi, M., Passos, I. D., & Mironidou‐Tzouveleki, M. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1011805
Exosome-mediated tumor immunology and the application of synthetic biology in cancer treatment
Liu, C., Sun, B., Dong, W., Li, S., & Yumiao, Z. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0237
Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma
Bobak, K., Synoradzki, K. J., Sulejczak, D., Rutkowski, P. L., & Czarnecka, A. M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_179
Biomarkers of Prediction of Immunotherapy and Updates on CTLA-4 Therapy
Sobhani, N., Roudi, R., D’Angelo, A., & Generali, D. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_165
Exploring the prognostic value and biomarker of TEX11 in breast cancer via PANoptosis
Liu, J., Ma, W., Zhang, H., Shi, M., Lin, W., Huang, Z., & Yang, Y. (2025) · Breast Cancer · doi:10.1007/s12282-025-01794-4
Magentumoren
Möhler, M., & Cameron, S. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21164-5.00009-x
Terapias combinadas contra tumores murinos: inmunoterapia y quimioterapia. Relación de la eficacia del tratamiento con el estado inmunológico del portador
Maglioco, A. (2011) · Repositorio Digital Institucional de la Universidad de Buenos Aires (Universidad de Buenos Aires)
Estudo de alterações em células Treg e TH17 no linfonodo drenante de animais com tumores
Salin, M. M. (2014) · Americanae (AECID Library)
RNA Interference of CTLA4 in Human Leukaemia T Cells
Vassileva, R. (2013) · Arrow - TU Dublin (Technological University Dublin) · doi:10.21427/d7r595
Additional file 1 of CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC)
Liu, S., Wang, F., Tan, W., Zhang, L., Dai, F., Wang, Y., Fan, Y., Yuan, M., Yang, D., Zheng, Y., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13152015
Additional file 3 of Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
Saad, M., Lee, S. J., Tan, A. C., Naqa, I. M. E., Hodi, F. S., Butterfield, L. H., LaFramboise, W. A., Storkus, W. J., Karunamurthy, A. D., Conejo-Garcia, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20003373
Additional file 3 of Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response
Qi, H., Sun, Z., Gao, T., Yao, Y., Wang, Y., Li, W., Wang, X., Wang, X., Liu, D., & Jiang, J.-D. (2024) · Figshare · doi:10.6084/m9.figshare.26690719
Additional file 5 of Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response
Qi, H., Sun, Z., Gao, T., Yao, Y., Wang, Y., Li, W., Wang, X., Wang, X., Liu, D., & Jiang, J.-D. (2024) · Figshare · doi:10.6084/m9.figshare.26690725
Additional file 2 of Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
Saad, M., Lee, S. J., Tan, A. C., Naqa, I. M. E., Hodi, F. S., Butterfield, L. H., LaFramboise, W. A., Storkus, W. J., Karunamurthy, A. D., Conejo-Garcia, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20003370
Additional file 2 of Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response
Qi, H., Sun, Z., Gao, T., Yao, Y., Wang, Y., Li, W., Wang, X., Wang, X., Liu, D., & Jiang, J.-D. (2024) · Figshare · doi:10.6084/m9.figshare.25374844
Additional file 4 of Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response
Qi, H., Sun, Z., Gao, T., Yao, Y., Wang, Y., Li, W., Wang, X., Wang, X., Liu, D., & Jiang, J.-D. (2024) · Figshare · doi:10.6084/m9.figshare.26690722
Additional file 1 of Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
Saad, M., Lee, S. J., Tan, A. C., Naqa, I. M. E., Hodi, F. S., Butterfield, L. H., LaFramboise, W. A., Storkus, W. J., Karunamurthy, A. D., Conejo-Garcia, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20003367
Additional file 1 of Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response
Qi, H., Sun, Z., Gao, T., Yao, Y., Wang, Y., Li, W., Wang, X., Wang, X., Liu, D., & Jiang, J.-D. (2024) · Figshare · doi:10.6084/m9.figshare.25374741
Checkpoint inhibitors in cancer Immunotherapy: Mechanisms, Resistance, and Combination Strategies
Shah, R. K., Raval, Y., Shaikh, M., Hadiya, J., Hirpara, F., Makwana, S., & Tirgar, P. (2026) · EPJ Web of Conferences · doi:10.1051/epjconf/202634801013
Spatial immune hubs defined by conserved activated dendritic cells are remodeled by immunotherapyPreprint
Minowa, T., Keshari, S., He, S., Saha, A., Shavkunov, A. S., Pineda, J. E., Yeo, Y. Y., Zhu, B., Mohanty, V., Jindal, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.10.703136
Immune-related adverse events in patients with preexisting myasthenia gravis and thymoma following immune checkpoint inhibitor treatment: a retrospective, observational study
Sun, C., Guo, R., Yin, X., Feng, L., Guo, Y., Xu, Y., Hao, S., Huang, X., Song, N., Gao, T., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1635001
The crosstalk between dying tumor cells and immune effectors within tumor microenvironment elicited by anti-cancer therapies dictates the therapeutic outcome
Ma, Y. (2011) · theses.fr (ABES) · doi:10.70675/fab82024zd70bz47e3za57ez7a2753685cd9
Role and prognostic importance of regulatory T cells in lung cancer patients, according to the presence of tertiary lymphoid structures
Devi-Marulkar, P. (2015) · theses.fr (ABES) · doi:10.70675/1afef94czc6daz4936zb0d3z44f75d1762b1
Impact des inhibiteurs de la voie mTOR sur la réponse immunitaire T anti-tumorale
Beziaud, L. (2015) · theses.fr (ABES) · doi:10.70675/02936eacz6998z4fd1zb56cz2535d854411e
Cancers du sein et immunité anti-tumorale
Mombelli, S. (2014) · theses.fr (ABES) · doi:10.70675/0f728c2fzfbb3z4cd8z9c09zad87af4858da
Implication of immune system in chondrosarcoma progression and therapeutic response : Could immunotherapy play a role in chondrosarcoma treatment ?
Simard, F. A. (2016) · theses.fr (ABES) · doi:10.70675/69d89730z693dz4330za234z5f8e56bde8d7 · Cited by 1
Etude du rôle de NF-kB dans les lymphocytes T régulateurs chez la souris
Ronin, É. (2017) · theses.fr (ABES) · doi:10.70675/ea12e750z64e5z437fza120z3bbe647a2642
Immunostimulatory and Oncolytic Properties of Rotavirus Can Overcome Resistance to Immune Checkpoint Blockade Therapy
Shekarian, T. (2017) · theses.fr (ABES) · doi:10.70675/31550ddbz6cf7z4e25za126z01b3fb8737f1
Caractérisation anatomo-clinique et phénotypique des adénocarcinomes canalaires du pancréas avec instabilité des microsatellites
Lupinacci, R. M. (2017) · doi:10.70675/f5537d9ezcd37z45ddzb27ez9d26e852f638
Rôle de la sphingosine kinase-1 dans la réponse immunitaire anti-tumorale et dans le traitement du mélanome par immunothérapie
Imbert, C. (2018) · theses.fr (ABES) · doi:10.70675/4f7c1702zf576z4f67z8913zeb5fdc0f59f6
Améliorer les effets anti-tumoraux des lymphocytes T folliculaires helper (Tfh) en ciblant la communication intercellulaire entre Tfh et Th2.
Mary, R. (2019) · theses.fr (ABES) · doi:10.70675/61ce3e60z2d08z4e4czbe68z80c4f5563cd0
The Immune Modulation Role of Low Dosage of Cyclosporin-A (LdCsA) in the Antitumor Response of the Adaptive Immune System
Torres, C. F. (2019) · theses.fr (ABES) · doi:10.70675/119b681az980fz4e38z913cz31aba51f868c
L'absence de CD226 caractérise des LT CD8+ hyporépondeurs au TCR et aux fonctions antitumorales défectueuses
Weulersse, M. (2019) · theses.fr (ABES) · doi:10.70675/2a56dbcazd721z44daz9b18z27d6c10e6137
Characterization of the Tumor Microenvironment in Chronic Lymphocytic Leukemia by Mass Cytometry : Implications for Immunotherapy
Wierz, M. (2020) · theses.fr (ABES) · doi:10.70675/80454a47z3b6bz4b8bza0c3z684d69f087b3
Local Anti-CTLA4 Cancer Immunotherapy From Bench to Bedside
Tselikas, L. (2021) · theses.fr (ABES) · doi:10.70675/7e1fa4d8z5408z419bz9394z19ae17697026
EVT-701 : targeting electron transport chain complex I as therapeutic approach in cancer
Yolba, R. L. (2021) · theses.fr (ABES) · doi:10.70675/9cadea77z03ccz4a54zb381zf34a432615a5
Rôle des lymphocytes T Résidents Mémoires (TRM) et des intégrines CD103 et CD49a dans la réponse aux immunothérapies ciblant PD-1 et CTLA-4
Damei, I. (2022) · theses.fr (ABES) · doi:10.70675/415eefc7z95c8z492ez89beze36410b45ef5
Characterizing Resistance Mechanisms to Immune Checkpoint Blockades in Mismatch Repair-Deficient Tumors
Nebot-Bral, L. (2021) · theses.fr (ABES) · doi:10.70675/e1797b79z28d4z4e65zbd29zdc771b604d21
Contribution des réponses immunitaires adaptatives spécifiques des antigènes tumoraux à l'efficacité clinique de l'immunothérapie par inhibition de l'axe PD-1/PD-L1
Balança, C.-C. (2021) · theses.fr (ABES) · doi:10.70675/35353ecez3292z48f1z81ecz10edb0a3d321
Optimisation des vaccins peptidiques anti-cancers à but thérapeutique par l'utilisation d'un vecteur omposé de nanotubes de nitrure de bore et combinaisons avec les anticorps anti-PD-L
Rangan, L. (2020) · theses.fr (ABES) · doi:10.70675/b07e22f8z2334z4497z89b0ze8df4b6869cd
Defining the differential contributions of CD4+ and CD8+ T cells to CAR T cell therapy against B cell malignancies
Boulch, M. (2022) · theses.fr (ABES) · doi:10.70675/580ab96fzaff1z4acfz8156z822dc6e5f3d7
Thérapies du cancer de nouvelle génération et fonctions cognitives : Nouveaux concepts, nouveaux mécanismes, biomarqueurs originaux.
Coppola, N. (2023) · theses.fr (ABES) · doi:10.70675/0eaeed03z4d50z4014z947czedd9a2ec2c91
The gut microbiota as a modulator of CAR T cells therapy efficacy : role for Akkermansia supplementation via the AhR pathway
Marcos-Kovandzic, L. (2024) · theses.fr (ABES) · doi:10.70675/3bde4b45z23ecz4b69zb90dzabccd7cd7fca
B7 costimulation antagonizes RORγt+ regulatory T cells and immune tolerance in the intestine
Lyu, M., & Sonnenberg, G. F. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20251094
Tumor-infiltrating FOXP3+ Regulatory T Cells in Solid Malignancies: Prognostic and Immunotherapeutic Perspectives
Suvvari, T. K., Siripurapu, Y. S. L. R., & Kocharlakota, S. V. (2025) · Journal of Current Oncology · doi:10.1177/25898892261445162
Thorax cancer: Tumor microenvironment
Sheth, D., Rahman, S., & Pathak, Y. V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36783-0.00007-1
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy–Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones
George, M. M., Hamadene, L., Marouf, Y., Ceglia, N., Hirschhorn, D., Schulze, I., Dong, L., Venkatesh, D., Maniyar, R. R., Budhu, S., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3863
Encapsulated cell therapy for local anti-CTLA-4 delivery in cancer immunotherapy
Engel, A., Vernet, R., Charrier, E., Urwyler, M., Rohr, O. V., Saingier, V., Courtout, F., Abukscem, S., Bouvarel, T., Lathuilière, A., et al. (2026) · iScience · doi:10.1016/j.isci.2026.116938
Structural Foundation of CTLA-4 antibodies: Emerging Platforms for Next-generation Cancer Immunotherapy
Leta, E. M., Syed, S., Binegde, G. N., Gu, D., Xiong, J., & Wang, F. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117405
Immune Checkpoint Inhibitors and Related Immunotherapies
Machado, S., & Cardoso, A. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-3373-6551-0.ch007
Biodegradable microparticles for in situ immunization against cancer
Makkouk, A., Norian, L. A., Monick, M., Weiner, G. J., Lubaroff, D., & Salem, A. (2014) · doi:10.17077/etd.sl8jfuqu
The effects of environmental oxygen on CD4+ T lymphocyte activation and responses
Clay, E. (2015) · University of Birmingham Institutional Research Archive (University of Birmingham)
SELECTION METHODS FOR GENETICALLY-MODIFIED T CELLS: IN SUPPORT OF TRANSLATIONAL THERAPY
Rushworth, D. (2015) · Digital Commons-TMC (Texas Medical Center)

Authors: Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
University of Massachusetts Chan Medical School (US)
Medarex, Inc., Milpitas, CA 95035 3
Corresponding author: Allison, James P.
ORCID: Peggs, Karl S.
Quezada, Sergio A.
Korman, Alan J.
Allison, James P.
Venue: Journal of Experimental Medicine
Publisher: Rockefeller University Press
Published: 2009-07-06
Volume: 206
Issue: 8
Pages: 1717-1725
ISSN: 0022-1007 (ISSN-L)
1540-9538
DOI: 10.1084/jem.20082492
PMC: PMC2722174
OpenAlex: W2013043293
Cited by: 967
References: 34
Citations by year: 2026: 17 · 2025: 46 · 2024: 57 · 2023: 56 · 2022: 51 · 2021: 54 · 2020: 59 · 2019: 64 · 2018: 78 · 2017: 82 · 2016: 78 · 2015: 81 · 2014: 56 · 2013: 60 · 2012: 39
FWCI: 20.80
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: The Journal of Experimental Medicine (publishedVersion)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: Howard Hughes Medical Institute
Cancer Research Institute
Bristol-Myers Squibb
Memorial Sloan-Kettering Cancer Center
University College London
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4, anti-CTLA-4 antibody, regulatory T cells, effector T cells, cancer immunotherapy, melanoma, immune checkpoint blockade, humanized mice, antitumor immunity, T cell tolerance
MeSH terms: Animals, Antibodies, Neoplasm, Humans, Immunosuppression Therapy, Immunotherapy, Melanoma, Experimental, Mice, Inbred C57BL, Mice, Transgenic, Recombinant Proteins, Antigens, CD, T-Lymphocyte Subsets, Mice, Knockout, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, CTLA-4 Antigen, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks